Molecular imaging plays a role in personalizing treatment for prostate cancer, liver cancer, neuroendocrine tumors, and thyroid cancer.
Prostate cancer
01Liver cancer
01Neuroendocrine tumors
01Thyroid cancer
01
Data and images courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
Theranostics for thyroid cancer
131I xSPECT Quant enables quantification of residual thyroid tissue to determine therapeutic dose
- SPECT/CT with xSPECT Quant acquisition performed 24 hours following a diagnostic dose of 131I in a patient with a thyroid carcinoma post total thyroidectomy to determine accurate 131I therapeutic dose
- xSPECT Quant-based calculation of absolute tracer concentration shows high 131I concentration in residual thyroid tissue with SUVmax of 10.29
- 131I xSPECT Quant enables quantification of residual tissue to determine therapeutic dose
Data courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
Theranostics for prostate cancer (PSMA)
15-minute, whole-body SPECT/CT with xSPECT Quant provides high sensitivity to assess 177Lu-PSMA therapy response
- Patient with a history of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) underwent 6 cycles of 177Lu-PSMA treatment
- Cycle 6 ,177Lu-PSMA, 3-bed position xSPECT Quant imaging confirmed positive treatment response
- There is an overall increased extent of PSMA-avid cervical, thoracic, and abdominopelvic nodal metastasis
Data courtesy of Tufts Medical Center, Boston, Massachusetts, USA.
Theranostics for liver cancer
SPECT/CT evaluation of liver tumor perfusion with hepatic arterial catheter infusion of 99mTc-MAA prior to SIRT
- Patient with hepatocellular carcinoma evaluated for 90Y-microsphere radioembolization, selective internal radiation therapy (SIRT)
- SPECT/CT following infusion of 99mTc MAA through hepatic arterial catheter to evaluate liver tumor perfusion and lung shunt fraction
- Study shows perfusion limited to the periphery of large tumor with large central necrosis, which shows absence of any perfusion
- Low-dose CT sharply delineates necrotic tumor margin, highlighting the adjacent tracer uptake
Data courtesy of 210 PET Imaging, Cary, North Carolina, USA.
Theranostics for neuroendocrine tumors
64Cu-DOTATATE PET/CT delineates multiple neuroendocrine tumor metastases for precise diagnosis and patient therapy selection
- 80-year-old male with ascities, abdominal pain, and weight loss. CT revealed peritoneal and mesenteric nodules. Pathology confimed well-differentiated neuroendocrine tumor. Patient referred for PET/CT staging for therapy decision.
- 64Cu-DOTATATE PET/CT shows high contrast within metatstatic lesions throughout the chest, abdomen, and pelvis, suggesting possibility of success with radionuclide therapy
Data and images courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
Theranostics for thyroid cancer
131I xSPECT Quant enables quantification of residual thyroid tissue to determine therapeutic dose
- SPECT/CT with xSPECT Quant acquisition performed 24 hours following a diagnostic dose of 131I in a patient with a thyroid carcinoma post total thyroidectomy to determine accurate 131I therapeutic dose
- xSPECT Quant-based calculation of absolute tracer concentration shows high 131I concentration in residual thyroid tissue with SUVmax of 10.29
- 131I xSPECT Quant enables quantification of residual tissue to determine therapeutic dose
Data courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
Theranostics for prostate cancer (PSMA)
15-minute, whole-body SPECT/CT with xSPECT Quant provides high sensitivity to assess 177Lu-PSMA therapy response
- Patient with a history of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) underwent 6 cycles of 177Lu-PSMA treatment
- Cycle 6 ,177Lu-PSMA, 3-bed position xSPECT Quant imaging confirmed positive treatment response
- There is an overall increased extent of PSMA-avid cervical, thoracic, and abdominopelvic nodal metastasis
Data courtesy of Tufts Medical Center, Boston, Massachusetts, USA.
Theranostics for liver cancer
SPECT/CT evaluation of liver tumor perfusion with hepatic arterial catheter infusion of 99mTc-MAA prior to SIRT
- Patient with hepatocellular carcinoma evaluated for 90Y-microsphere radioembolization, selective internal radiation therapy (SIRT)
- SPECT/CT following infusion of 99mTc MAA through hepatic arterial catheter to evaluate liver tumor perfusion and lung shunt fraction
- Study shows perfusion limited to the periphery of large tumor with large central necrosis, which shows absence of any perfusion
- Low-dose CT sharply delineates necrotic tumor margin, highlighting the adjacent tracer uptake
Data courtesy of 210 PET Imaging, Cary, North Carolina, USA.
Theranostics for neuroendocrine tumors
64Cu-DOTATATE PET/CT delineates multiple neuroendocrine tumor metastases for precise diagnosis and patient therapy selection
- 80-year-old male with ascities, abdominal pain, and weight loss. CT revealed peritoneal and mesenteric nodules. Pathology confimed well-differentiated neuroendocrine tumor. Patient referred for PET/CT staging for therapy decision.
- 64Cu-DOTATATE PET/CT shows high contrast within metatstatic lesions throughout the chest, abdomen, and pelvis, suggesting possibility of success with radionuclide therapy
Data and images courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
Theranostics for thyroid cancer
131I xSPECT Quant enables quantification of residual thyroid tissue to determine therapeutic dose
- SPECT/CT with xSPECT Quant acquisition performed 24 hours following a diagnostic dose of 131I in a patient with a thyroid carcinoma post total thyroidectomy to determine accurate 131I therapeutic dose
- xSPECT Quant-based calculation of absolute tracer concentration shows high 131I concentration in residual thyroid tissue with SUVmax of 10.29
- 131I xSPECT Quant enables quantification of residual tissue to determine therapeutic dose
